Phase II study of anguidine in gastrointestinal malignancies: a Southwest Oncology Group study.

Abstract

The Southwest Oncology Group conducted a phase II study of anguidine in 134 patients with gastrointestinal malignancies. Anguidine was administered as a 4-hour infusion at doses of 3.0 and 4.5 mg/m2 daily x 5. Response rates for patients with colon carcinoma were 22% (four of 18 patients without previous chemotherapy) and 6% (four of 63 patients with previous chemotherapy). There were no responses in patients with pancreatic cancer (four patients) or gastric cancer (six). Toxic effects included thrombocytopenia (19.8%), leukopenia (18.8%), nausea and vomiting (49%), hypotension (37%), and confusion (12%). Antitumor activity of anguidine in patients with colon cancer may be similar to that of 5-FU, but nonhematologic toxicity is substantial.

• Authors: R Bukowski, C Vaughn, R Bottomley, T Chen
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 66 Issue 2 Pg. 381-3 (Feb 1982) ISSN: 0361-5960 [Print] United States
• PMID: 7055820 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Sesquiterpenes
• Trichothecenes
• diacetoxyscirpenol

Topics

• Aged
• Drug Evaluation
• Gastrointestinal Neoplasms (drug therapy)
• Humans
• Sesquiterpenes (therapeutic use)
• Trichothecenes (adverse effects, therapeutic use)